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Antipsychotic-induced tardive dyskinesia is a potentially 
irremediable and debilitating condition with the onset 
most commonly associated with the use of first-generation 
antipsychotics.1 The development of tardive dyskinesia on 
clozapine, a second-generation antipsychotic, is uncommon, 
and the drug is therefore a treatment option for those patients 
who develop the syndrome following treatment with first-
generation agents. I report on the case of a 27-year-old man 
who developed severe tardive dyskinesia following initiation of 
clozapine treatment. To the best of my knowledge, this is the 
first case of tardive dyskinesia associated with clozapine use 
reported in South Africa.
Case presentation
A 27-year-old single man was admitted to a psychiatric 
hospital for the first time in June 2006, with a diagnosis of 
substance-induced psychosis. He had a history of regular illicit 
polysubstance abuse from the age of 14 years (mostly cannabis 
and methaqualone (Mandrax) and methamphetamine (tik) abuse 
from 2005.
He was discharged on chlorpromazine following his first 
hospital admission of 3 weeks after an initial unsuccessful trial 
of haloperidol. Although there was no history of continued 
substance abuse after his first hospital admission, he relapsed 
6 months later and was re-admitted to hospital. The diagnosis 
was revised to schizophrenia. Clozapine was initiated and 
titrated up to 200 mg/day over a period of 2 weeks. His 
psychotic symptoms improved but depressive symptoms 
emerged, including dysphoria and suicidal ideation. Fluoxetine 
was commenced with good effect. Investigations, including a 
computed tomography (CT) head scan, full blood count, HIV 
ELISA test, thyroid function test and rapid plasma reagin (RPR) 
screen were done but the results were unremarkable. He was 
discharged after 4 months – euthymic, apsychotic and with no 
extrapyramidal features. He maintained regular community clinic 
reviews with good medication compliance and no evidence 
of ongoing substance abuse, and no adverse effects were 
reported.
In March 2007, onset of orobuccal dyskinesia was noted. 
Fluoxetine was immediately stopped but he continued on 
clozapine 200 mg/daily. The dyskinesia progressively 
worsened over the following 4 months. In July 2007, he was 
re-admitted to hospital, overtly distressed by severe orofacial 
dyskinesia with involvement of the oesophagus, as well as upper- 
and lower-limb dyskinesia. His symptoms were incapacitating 
as he struggled to chew and swallow and he also complained 
of a re-emergence of suicidal thoughts, auditory hallucinations 
and feeling dysphoric. The severity of his dyskinesia was rated 
as 30 (severe) on the Abnormal Involuntary Movement Scale 
(AIMS). Apart from severe dyskinesia, his physical examination 
was unremarkable. Clozapine was stopped and regular oral 
diazepam was administered, with significant improvement of 
symptoms within days. Diazepam was thereafter substituted 
with a regular dose of clonazepam 1 mg twice daily. A 
repeat full blood count (FBC), HIV screen, thyroid screen, RPR, 
caeruloplasmin and antistreptolysin O titre (ASOT) were done. 
Results were within normal limits. A repeat CT head scan and an 
EEG were non-contributory. However, a SPECT scan showed left 
basal ganglia hypoperfusion, as well as decreased perfusion in 
the left thalamus, left parietal area and striatum. The abnormal 
limb movements improved after discontinuation of clozapine but 
he remained distressed by the ongoing orofacial dyskinesia. At 
the time of reporting, he had been on clonazepam for 7 weeks 
and a gradually increasing dosage of quetiapine. His AIMS 
score 8 weeks after stopping clozapine had improved to 19 
(moderate) and, although the mood symptoms resolved, the 
psychosis had worsened.
Discussion
The atypical or second-generation antipsychotic agents 
(SGAs) are often drugs of choice in the treatment of psychotic 
illness, based on evidence of their reduced risk for associated 
acute extrapyramidal side-effects and tardive dyskinesia, 
compared with the first-generation antipsychotics (FGAs).1-3 The 
pathophysiology of the antidyskinetic properties of atypical 
antipsychotics, as well as the pathophysiology of tardive 
dyskinesia itself, remains unclear.4
The clinical benefits of the use of SGAs in patients with tardive 
dyskinesia appear to be twofold. They may ameliorate the 
symptoms of pre-existing tardive dyskinesia, and are also 
less likely to induce tardive dyskinesia. Evidence for the lower 
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incidence of tardive dyskinesia associated with the SGAs is 
highlighted in a recent systematic review. The authors concluded 
that the annual incidence of tardive dyskinesia associated 
with the use of second-generation antipsychotics is 3.9%, as 
compared with an incidence of 5.5% for the first-generation 
agents.2
It is difficult to determine whether clozapine induces tardive 
dyskinesia, because treatment with the agent is often initiated 
only after a patient has had prolonged exposure to other 
psychotropic agents, including high-dose FGAs. Furthermore, 
the paucity of prospective clinical trial data has not provided 
any statistically significant proof of increased risk for tardive 
dyskinesia with clozapine use and, in some studies, results 
have been equivocal.5,6 Evidence for clozapine-induced tardive 
dyskinesia has therefore largely been based on case reports in 
the literature.6,7
In this case, it could be argued that previous methamphetamine 
abuse might have predisposed the patient to developing tardive 
dyskinesia. Methamphetamine abuse has been implicated 
in the onset of hyperkinetic disorders including chorea.8 One 
could further speculate on whether our patient developed 
tardive dyskinesia on the basis of exposure to fluoxetine. 
However, the onset of the dyskinesia was 20 months after his 
last methamphetamine exposure, and the dyskinesia increased 
in severity for a period of 4 months after fluoxetine had been 
withdrawn and while he was still on clozapine. A marked 
improvement in the dyskinetic movements was observed after 
clozapine was discontinued, however, which therefore suggests 
that clozapine was the most likely causative agent.
This report highlights the possibility of the emergence of tardive 
dyskinesia with the use of clozapine. Although the occurrence 
rate is lower than that associated with the use of first-generation 
antipsychotics, it is important for clinicians to be aware of the 
potential risk of tardive dyskinesia in patients being treated with 
clozapine.
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